Dermal fibroblast signaling pathways

Dermal fibroblast signaling pathways encompass the complex network of biochemical signals that regulate the behavior of fibroblasts within the skin's dermis. These pathways, most notably the Transforming Growth Factor-beta (TGF-β)/Smad, Wnt/β-catenin, and Platelet-Derived Growth Factor (PDGF) cascades, are essential for maintaining skin homeostasis and coordinating the response to injury (Source: NIH, PMC4276682). In a healthy state, these signals manage the production and remodeling of the extracellular matrix (ECM). However, chronic activation of these pathways leads to pathological conditions such as systemic sclerosis, keloids, and hypertrophic scarring, characterized by excessive collagen deposition (Source: PubMed, 28841359). Conversely, the decline of these signaling activities is a primary driver of skin aging and the development of chronic, non-healing wounds. While individual components of these pathways, such as specific tyrosine kinase receptors or ligands, are targeted by drugs like Nintedanib or Fresolimumab, the term "Dermal fibroblast signaling pathways" refers to a broad biological system rather than a single therapeutic target. Understanding these integrated networks is crucial for developing precision therapies that can selectively modulate skin repair without inducing systemic toxicity or impairing normal tissue maintenance.

Other names

Skin fibroblast signalingFibroblast activation pathwaysDermal signaling cascades

Modulation of intracellular and extracellular signaling cascades, such as TGF-beta/Smad, Wnt/beta-catenin, and MAPK/ERK, to regulate fibroblast activation, myofibroblast differentiation, and collagen synthesis.